NCT05607446

To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis

A Single-center, Randomized, Double-blind, Two-cycle, Two-way Crossover Phase Ib Study to Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A clinical study to evaluate the efficacy and safety of tqc3564 tablets in the treatment of persistent allergic rhinitis. A total of 24 patients will be enrolled.

Conditions

• Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	TQC3564 tablets	TQC3564 tablets are CRTH2 antagonists.
DRUG	Placebo tablets	The intervention drug is placebo.
DRUG	TQC3564 tablets, montelukast sodium tablets	The intervention drugs are TQC3564 tablets combined with montelukast sodium tablets. TQC3564 is a CRTH2 antagonist, montelukast sodium is Leukotriene receptor antagonist.
DRUG	Placebo tablets, montelukast sodium tablets	The intervention drugs are placebo combined with montelukast sodium tablets. Montelukast sodium is Leukotriene receptor antagonist.

Timeline

• Start date: 2022-09-14
• Primary completion: 2023-05-09
• Completion: 2023-12-14
• First posted: 2022-11-07
• Last updated: 2024-11-26

Locations

1 site across 1 country: China